OpenLB
Open Library of Bioscience
Advanced Search
Vaccines
Dec 29, 2023;12 (1):

Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies.

Hui Wang, Shuxian Wang, Ren Fang, Xiaotian Li, Jiayin Xing, Zhaoli Li, Ningning Song
Author Information
  1. Hui Wang: Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, China.
  2. Shuxian Wang: Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, China.
  3. Ren Fang: Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, China.
  4. Xiaotian Li: Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, China.
  5. Jiayin Xing: Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, China.
  6. Zhaoli Li: SAFE Pharmaceutical Technology Co., Ltd., Beijing 100000, China.
  7. Ningning Song: Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, China. ORCID
PMID: 38250851 DOI: 10.3390/vaccines12010038

Abstract

Tuberculosis (TB) remains a global infectious disease primarily transmitted via respiratory tract infection. Presently, vaccination stands as the primary method for TB prevention, predominantly reliant on the Bacillus Calmette-Gu��rin (BCG) vaccine. Although it is effective in preventing disseminated diseases in children, its impact on adults is limited. To broaden vaccine protection, efforts are underway to accelerate the development of new TB vaccines. However, challenges arise due to the limited immunogenicity and safety of these vaccines, necessitating adjuvants to bolster their ability to elicit a robust immune response for improved and safer immunization. These adjuvants function by augmenting cellular and humoral immunity against antigens via different delivery systems, ultimately enhancing vaccine efficacy. Therefore, this paper reviews and summarizes the current research progress on vaccines and their associated adjuvants, aiming to provide a valuable reference for the development of novel TB vaccines and the screening of adjuvants.

Keywords

TB adjuvant vaccine

References

  1. RSC Adv. 2023 Jan 11;13(3):1727-1737 [PMID: 36712647]
  2. Vaccines (Basel). 2023 Jun 29;11(7): [PMID: 37514991]
  3. Eur J Pharm Sci. 2014 Oct 1;62:227-42 [PMID: 24909731]
  4. Nat Commun. 2022 Feb 1;13(1):602 [PMID: 35105879]
  5. J Control Release. 2020 Jul 10;323:125-137 [PMID: 32247804]
  6. Curr Opin Infect Dis. 2023 Oct 1;36(5):385-393 [PMID: 37462930]
  7. NPJ Vaccines. 2022 Nov 7;7(1):138 [PMID: 36344523]
  8. Lancet Respir Med. 2015 Mar;3(3):190-200 [PMID: 25726088]
  9. Lancet Infect Dis. 2022 Oct;22(10):1472-1483 [PMID: 35772447]
  10. Expert Rev Anticancer Ther. 2021 Aug;21(8):841-851 [PMID: 33831324]
  11. Vaccines (Basel). 2020 Sep 22;8(3): [PMID: 32971761]
  12. Biomaterials. 2021 Jan;268:120597 [PMID: 33360074]
  13. Immun Inflamm Dis. 2023 Jun;11(6):e867 [PMID: 37382263]
  14. J Immunol. 2011 May 1;186(9):5413-24 [PMID: 21451109]
  15. Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856 [PMID: 36727201]
  16. Pathogens. 2022 Nov 30;11(12): [PMID: 36558778]
  17. PLoS Pathog. 2008 Feb 8;4(2):e33 [PMID: 18282096]
  18. Expert Opin Ther Targets. 2019 Oct;23(10):865-882 [PMID: 31580163]
  19. Vaccines (Basel). 2021 Apr 16;9(4): [PMID: 33923628]
  20. Viruses. 2023 Aug 18;15(8): [PMID: 37632102]
  21. Vaccine. 2021 Dec 8;39(50):7277-7285 [PMID: 34238608]
  22. Expert Rev Vaccines. 2017 Jan;16(1):55-63 [PMID: 27448771]
  23. Tuberculosis (Edinb). 2023 Jan;138:102302 [PMID: 36586154]
  24. Vaccines (Basel). 2020 Nov 03;8(4): [PMID: 33153191]
  25. Drug Discov Today. 2023 Feb;28(2):103458 [PMID: 36427779]
  26. Vaccine. 2020 Jan 22;38(4):779-789 [PMID: 31735500]
  27. Carbohydr Polym. 2017 Nov 1;175:746-755 [PMID: 28917925]
  28. Iran J Allergy Asthma Immunol. 2018 Jun;17(3):240-249 [PMID: 29908541]
  29. Front Immunol. 2017 Sep 19;8:1147 [PMID: 28974949]
  30. Nat Prod Rep. 2010 Jun;27(6):919-47 [PMID: 20393651]
  31. Vaccine. 2011 Jan 10;29(3):426-36 [PMID: 21093498]
  32. J Control Release. 2012 Jul 20;161(2):505-22 [PMID: 22353619]
  33. Front Immunol. 2022 Jun 23;13:895020 [PMID: 35812383]
  34. Vaccines (Basel). 2022 May 23;10(5): [PMID: 35632581]
  35. PLoS One. 2016 Mar 24;11(3):e0152200 [PMID: 27011018]
  36. Int J Mol Sci. 2020 Sep 09;21(18): [PMID: 32916818]
  37. Int Immunopharmacol. 2023 Nov;124(Pt B):111060 [PMID: 37862738]
  38. Microb Pathog. 2018 Aug;121:218-223 [PMID: 29800697]
  39. J Leukoc Biol. 2021 May;109(5):991-998 [PMID: 33527516]
  40. Nat Rev Immunol. 2019 Sep;19(9):550-562 [PMID: 31114037]
  41. Methods Mol Biol. 2021;2197:51-85 [PMID: 32827132]
  42. J Nanobiotechnology. 2017 Nov 17;15(1):83 [PMID: 29149896]
  43. Methods Mol Biol. 2017;1654:377-388 [PMID: 28986806]
  44. Clin Infect Dis. 2018 Feb 1;66(4):554-563 [PMID: 29028973]
  45. Front Immunol. 2021 Oct 12;12:745625 [PMID: 34712234]
  46. FEMS Immunol Med Microbiol. 2011 Mar;61(2):197-204 [PMID: 21204995]
  47. Heliyon. 2023 Sep 15;9(9):e19925 [PMID: 37809683]
  48. Lancet Respir Med. 2021 Apr;9(4):373-386 [PMID: 33306991]
  49. Cochrane Database Syst Rev. 2019 Apr 30;4:CD012915 [PMID: 31038197]
  50. Cells. 2021 Jan 05;10(1): [PMID: 33466444]
  51. JCI Insight. 2022 Feb 8;7(3): [PMID: 34990408]
  52. Int Immunol. 2008 Jul;20(7):849-60 [PMID: 18469327]
  53. Vaccine. 2019 May 27;37(24):3167-3178 [PMID: 31047671]
  54. Expert Rev Vaccines. 2011 Apr;10(4):499-511 [PMID: 21506647]
  55. Clin Vaccine Immunol. 2006 Aug;13(8):898-904 [PMID: 16893990]
  56. PLoS One. 2021 Nov 12;16(11):e0258389 [PMID: 34767571]
  57. mBio. 2018 Oct 16;9(5): [PMID: 30327445]
  58. Tuberculosis (Edinb). 2023 Mar;139:102307 [PMID: 36706503]
  59. Vaccines (Basel). 2023 Aug 07;11(8): [PMID: 37631902]
  60. J Immunol. 2012 May 15;188(10):4828-37 [PMID: 22504654]
  61. Expert Rev Vaccines. 2015 Feb;14(2):221-34 [PMID: 25540984]
  62. Appl Microbiol Biotechnol. 2021 Apr;105(8):3131-3143 [PMID: 33834253]
  63. Nat Rev Drug Discov. 2021 Nov;20(11):817-838 [PMID: 34433919]
  64. J Microbiol Immunol Infect. 2015 Dec;48(6):597-603 [PMID: 24863497]
  65. Mol Cancer. 2021 Feb 16;20(1):33 [PMID: 33593376]
  66. Vaccine. 2014 Sep 8;32(40):5149-55 [PMID: 25066736]
  67. Int J Cancer. 2014 Apr 1;134(7):1683-94 [PMID: 24105486]
  68. Mol Ther Nucleic Acids. 2022 Feb 15;27:1235-1248 [PMID: 35282413]
  69. Vaccine. 2004 Sep 3;22(25-26):3274-84 [PMID: 15308350]
  70. Nat Commun. 2021 Nov 22;12(1):6774 [PMID: 34811370]
  71. Vaccine. 2014 Feb 3;32(6):712-6 [PMID: 24300592]
  72. ACS Chem Biol. 2022 Nov 18;17(11):3047-3058 [PMID: 35142488]
  73. Lancet Respir Med. 2015 Dec;3(12):953-62 [PMID: 26598141]
  74. Front Bioeng Biotechnol. 2022 May 10;10:903424 [PMID: 35620473]
  75. Int J Infect Dis. 2023 May;130 Suppl 1:S47-S51 [PMID: 36963657]
  76. Front Microbiol. 2022 Aug 26;13:935444 [PMID: 36090093]
  77. Vaccine. 2015 Jul 31;33(32):4025-34 [PMID: 26072017]
  78. Sci Transl Med. 2013 Oct 2;5(205):205ra134 [PMID: 24089406]
  79. Lancet Glob Health. 2023 Apr;11(4):e546-e555 [PMID: 36925175]
  80. Nanotechnology. 2022 Mar 17;33(23): [PMID: 35189608]
  81. Curr Microbiol. 2022 Jul 19;79(9):260 [PMID: 35852636]
  82. Pharmaceutics. 2020 Jan 28;12(2): [PMID: 32013049]
  83. J Immunother Cancer. 2022 Jul;10(7): [PMID: 35781395]
  84. N Engl J Med. 2018 Oct 25;379(17):1621-1634 [PMID: 30280651]
  85. Clin Infect Dis. 2023 Apr 3;76(7):1304-1310 [PMID: 36358012]
  86. Hum Vaccin Immunother. 2021 Oct 3;17(10):3539-3550 [PMID: 34288795]
  87. Vaccine. 2020 Oct 27;38(46):7239-7245 [PMID: 33004239]
  88. ACS Nano. 2021 Nov 23;15(11):16982-17015 [PMID: 34181394]
  89. J Control Release. 2012 Jul 20;161(2):363-76 [PMID: 22245687]
  90. Vaccine. 2006 Jun 29;24(26):5461-72 [PMID: 16678312]
  91. Microb Pathog. 2023 Nov;184:106372 [PMID: 37743026]

Grants

  1. 31873014/the National Natural Science Foundation of China
  2. 05430201/Youth Innovation Team Project for Talent Introduction and Cultivation in Universities of Shandong Province, China
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0TBvaccinevaccinesadjuvantsvialimiteddevelopmentTuberculosisremainsglobalinfectiousdiseaseprimarilytransmittedrespiratorytractinfectionPresentlyvaccinationstandsprimarymethodpreventionpredominantlyreliantBacillusCalmette-Gu��rinBCGAlthougheffectivepreventingdisseminateddiseaseschildrenimpactadultsbroadenprotectioneffortsunderwayacceleratenewHoweverchallengesarisedueimmunogenicitysafetynecessitatingbolsterabilityelicitrobustimmuneresponseimprovedsaferimmunizationfunctionaugmentingcellularhumoralimmunityantigensdifferentdeliverysystemsultimatelyenhancingefficacyThereforepaperreviewssummarizescurrentresearchprogressassociatedaimingprovidevaluablereferencenovelscreeningEnhancingVaccineEfficacy:CurrentProgressVaccinesAdjuvantsImmunizationStrategiesadjuvant

Similar Articles

Cited By